Cancer Treatment Reviews
Volume 31, Issue 8 , Pages 648-652 , December 2005

Adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin for survival in people with resected stage III colon cancer

  • C. Lamberti

      Affiliations

    • Corresponding Author InformationCorresponding author: Present address. Department of Internal Medicine I, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany. Tel.: +49 228 287 9098; fax: +49 228 287 9025.
    • ,
  • T. Sauerbruch
    • ,
  • A Glasmacher

References 

  1. Boland CR, Sinicrope FA, Brenner DE, Carethers JM. Colorectal cancer prevention and treatment. Gastroenterology. 2000;118:S115–S128
  2. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321–326
  3. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274–1281
  4. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291–297
  5. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097–4106
  6. Twelves C, Wong A, Nowacki M, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–2704
  7. Poplin E, Benedetti J, Estes N, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol. 2005;23:1819–1825
  8. Sakamoto J, Ohashi Y, Hamada C, et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol. 2004;22:484–492
  9. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351
  10. Wolmark N, Wieand S, Kuebler JP, Colangelo L, Smith RE. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 (2005 ASCO Annual Meeting Proceedings). J Clin Oncol. 2005;23:LBA3500
  11. van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts) (PETACC 3). J Clin Oncol. 2005;23:LBA8
  12. Schmoll HJ, Tabernero J, Nowacki M, Maroun J, Figer A, Price T, et al. Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer (2005 ASCO Annual Meeting Proceedings). J Clin Oncol. 2005;23:3523
  13. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  14. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  15. Popat S, Hubner R, Houlston R. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–618
  16. Peters G, Smorenburg C, Van Groeningen C. Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. J Chemother. 2004;16(Suppl. 4):25–30

☆ Sources of funding: Hoffmann–La Roche.

☆☆ For correspondence: Dr. Twelves, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford BD7 1DP, UK; e-mail: c.twelves@bradford.ac.uk.

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(05)00196-9

doi: 10.1016/j.ctrv.2005.09.009

Cancer Treatment Reviews
Volume 31, Issue 8 , Pages 648-652 , December 2005

Article Tools